Hib Vaccine Booster Dose Still to be Deferred

Please remember that the Hib vaccine booster dose administered at age 12-15 months should be deferred except for specific high-risk groups described below and in the Morbidity and Mortality Weekly Report (MMWR) published by the Centers for Disease Control and Prevention (CDC).

At this time, there are no immediate plans to change the interim recommendations. Please be aware of the interim recommendations and make every effort to follow them. This valuable resource is currently in limited supply. Please help us assure an equitable and appropriate public health use of this vaccine.

The basic interim recommendations are as follows:

- Defer administering the routine Hib vaccine booster administered at age 12-15 months except for specified high-risk groups.
- Certain children at increased risk for Hib disease, including children with asplenia, sickle cell disease, human immunodeficiency virus (HIV) infection and certain other immunodeficiency syndromes, and malignant neoplasms should continue to receive the full routinely recommended schedule including the 12-15 month booster dose.
- Children who are American Indians or Alaska Natives (AI/AN) should also continue to receive the full routinely recommended schedule including the 12-15 month booster dose. Providers who currently use PRP-OMP-containing Hib vaccines (PedvaxHib and Comvax) to serve predominantly AI/AN children in AI/AN communities should continue to use only PRP-OMP-containing Hib vaccines.
Links to the Mortality and Morbidity Weekly Report (MMWR) are provided below:

http://www.cdc.gov/mmwr/PDF/wk/mm5650.pdf

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5650a4.htm?s_cid=mm5650a4_e

The CDC shortage web site and a flyer that providers will receive with vaccine shipments can be found at the links below:

http://www.cdc.gov/vaccines/vac-gen/shortages/default.htm#hib


**Vaccines For Children (VFC) Vaccine Ordering Reminders**

- Proquad will not be available until early 2009. Please do not order Proquad at this time.
- Remember to fax your tally sheets to 317-234-3163. Please do not fax your tally sheets to 317-233-3719.
- You will need to use a Gardasil order form to order Gardasil. Orders for Gardasil that are written in on a regular vaccine order form will not be processed.
- Submitting an order without using your assigned order cycle form will slow processing of your order. Orders that are not submitted on the assigned order cycle form are set aside until all properly submitted orders have been processed.
- Do not return any vaccine to GIV. Vaccine returns must be shipped to McKesson.

If you need more information about these procedures, please call Judy or Laura at 800-701-0704

**HPV vaccine regimen in the Catch-up Immunization Schedule**

The HPV vaccine regimen in the Catch-up Immunization Schedule has been corrected. The entry to HPV vaccine was changed to:

<table>
<thead>
<tr>
<th>Dose 1 to 2</th>
<th>Dose 2 to 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 weeks</td>
<td>12 weeks</td>
</tr>
<tr>
<td>(and 24 weeks after the first dose)</td>
<td></td>
</tr>
</tbody>
</table>

This means that the third dose needs to be administered no earlier than 24 weeks after the first dose. The minimum intervals between dose one and dose two as well as between dose two and dose three remain unchanged.

The corrected Catch-up Schedule may be found at:

http://www.cdc.gov/vaccines/recs/schedules/child-schedule.htm#catchup
Frequently Asked Question: Incorporation of New Vaccines into the Vaccines For Children (VFC) Program

Question:
What is the process for including a new vaccine in the VFC program and how are immunization programs informed about the changes?

Answer:
The Advisory Committee on Immunization Practices (ACIP) has the advisory role to determine what vaccines should be recommended for administration to children, adolescents, and adults in the U.S. and the operational role to approve which vaccines should be available through the VFC program. The ACIP meets three times a year, and during these meetings newly licensed vaccines may be discussed and recommended for use. Once a vaccine is recommended by ACIP, a vote is taken about whether or not to include the new vaccine in the VFC program through consideration of a VFC resolution. VFC resolutions are specific to each vaccine and include who is eligible to receive the vaccine, the vaccination schedule, and precautions or contraindications to the vaccine. Once the VFC resolution is approved, CDC must negotiate a contract for the vaccine to make it available under the VFC program. VFC resolutions are posted on CDC’s website.

Vaccine Safety Information on the Internet

You can find information about these vaccine-related topics by visiting the Web sites listed below.

* The Centers for Disease Control and Prevention has information about vaccine safety, vaccine research, how vaccines are licensed, how safety is monitored, and how risks are communicated to the public. This information is available at [http://www.cdc.gov/vaccines/vac-gen/safety/default.htm](http://www.cdc.gov/vaccines/vac-gen/safety/default.htm).
* The Immunization Action Coalition Web site provides useful links to resources on issues ranging from thimerosal to autism. This information is available at [http://www.immunize.org/safety/index.htm](http://www.immunize.org/safety/index.htm).
* The Institute for Vaccine Safety provides an independent assessment of vaccines and vaccine safety to help guide decision makers and educate physicians, the public and the media about key issues surrounding the safety of vaccines. This information is available at [http://www.vaccinesafety.edu](http://www.vaccinesafety.edu).
* The National Network for Immunization Information offers information on thimerosal and autism, vaccine safety, and vaccine components. This information is available at [http://www.immunizationinfo.org/](http://www.immunizationinfo.org/).
* The U.S. Food and Drug Administration Web site has information on vaccines licensed for use and distribution in the U.S., the vaccine approval process, and vaccine safety. This information is available at [http://www.fda.gov/cber/vaccines.htm](http://www.fda.gov/cber/vaccines.htm).
* The Vaccine Adverse Event Reporting System (VAERS) Web site from the CDC and FDA has information about adverse events and possible side effects that occur after the administration of U.S. licensed vaccines. This information is available at [http://vaers.hhs.gov](http://vaers.hhs.gov).
Children and Hoosiers Immunization Registry Program (CHIRP)

Informational Sessions – New This Year!

CHIRP Informational Sessions are designed for NON-CHIRP users interested in learning more about the benefits of using CHIRP in their facility or practice. The agenda includes A) What is CHIRP; B) Benefits of using CHIRP; C) CHIRP’s role in State Funded vaccine; and D) How to enroll in CHIRP.

March 31, 2008
1:00pm – 2:30pm EST
Clarian Arnett South
Greenbush Clinic
2600 Greenbush St
Lafayette, IN 47904

CHIRP User Group Meeting – For Current CHIRP Users

This session is designed for CURRENT CHIRP users who are interested in learning about upcoming changes or who have specific questions regarding CHIRP usage. The agenda includes A) System Status; B) Current Issues; C) Upcoming Changes; D) Training – State Funded vaccine management and eligibility; E) Monitoring Data Quality; and F) Questions/Answers

Call (888) 227-4439 or go to the CHIRP.IN.GOV to register.
March 31, 2008
9:30pm – 11:30pm EST
The Kathryn Well Center
415 N 26th St
Lafayette, IN 47904

Contact Us

For questions and comments, please contact the ISDH Immunization Program at: Immunize@ISDH.IN.gov or 800-701-0704.